Please login to the form below
Biogen expands digital safety platform Assessa
The MS technolgy pilot, a collaboration with Ixico, will now include pharmacoviglance reporting
Biogen has expanded work on its digital safety platform, which helps monitor MS patients for signs of the rare and potentially fatel brain infection progressive multifocal leukoencephalopathy (PML).
The pilot programme, a collaboration with tech firm Ixico, will now include pharmacoviglance reporting to monitor patients for previously unreported adverse reactions.
The partners - who have been in a collaborative agreement since October 2015 - developed the Assessa system to provide neurologists with second opinion reading services if there is a suspicion of PML.
Giulio Cerroni, chief executive officer of Ixico, said: “We are delighted to announce the expansion of this pilot involving clinical experts in specialist MS centres and Biogen.
“The Assessa PML digital platform is intended to provide technology and speciality services to physcians involved in delivering care to people living with MS.”
Biogen has invested £1.5m in the project, which is currently being piloted in five EU countries.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
-
Account Manager
-
£Competitive Salary
-
Account Manager (PR)
-
Great Benefits
-
Senior External Communications Lead
-
£Competitive Salary
- Group Director of Medical Affairs and Scientific Strategy, Medic...
-
Substantial six figure package
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Account Director
-
£Competitive Salary
- Sanofi doses first patient in global Kevzara COVID-19 trial
- Moderna chairman says COVID-19 vaccine could begin phase 2 trials in spring
- Germany's coronavirus infections climb but deaths remain low
- Clinical trial of Gilead’s coronavirus hopeful remdesivir begins in UK
- Novartis donates malaria drug for COVID-19 clinical trials
- Takeda begins development of COVID-19 plasma therapy
- We’re Celebrating Ten Magical Years for Ify at Lucid Group
- NICE publishes new COVID-19 management guidelines
- Servier agrees to buy Symphogen to swell its cancer pipeline
- FDA approves expanded use of BMS’ Reblozyl in blood disorders
- Key emerging trends in digital health
- What challenges still face clinical trial recruitment and retention?
PMHub
Market Access Transformation
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...
Latest intelligence
- What challenges still face clinical trial recruitment and retention?
- Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
- “Fake News” and Credibility in Medical Publishing
- Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
- Delivering true value: what does it mean for KAM in cancer care?
- Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Quick links
Infographics
